Boston Scientific: Why the $5.4B Quarter and Insider Buying Make a Case to Buy the Dip
Boston Scientific reported a resilient quarter and insiders stepped in; valuation metrics and free cash flow argue the share-price damage looks overdone. This trade targets a rebound into the low-$60s over the next 45 trading days with a defined stop under $45 to limit downside.